Navigation Links
18-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto
Date:7/15/2008

SEATTLE, July 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Congress today passed the Medicare Improvements for Patients and Providers Act of 2008, which includes an 18-month extension of the 2007 reimbursement rate for radioimmunotherapies such as Zevalin(R) (Ibritumomab Tiuxetan), overriding President Bush's veto.

The bill was originally passed by the U.S. House of Representatives on June 24, 2008 and by the U.S. Senate on July 9, 2008. Last December, Congress froze reimbursement rates at the 2007 level for six months after the Centers for Medicare & Medicaid Services (CMS) released rates for 2008 that were lower than the acquisition cost for radioimmunotherapies.

Manufacturers of radioimmunotherapies have been in discussion with CMS on a payment policy that more accurately reflects hospital costs associated with the therapy. These drugs are used to fight relapsed non-Hodgkin's lymphoma (NHL), and can provide some patients with additional therapeutic options.

CTI purchased the U.S. sales, marketing, and development rights to Zevalin in late 2007 from Biogen Idec, Inc. Recently CTI reached an agreement with Bayer Schering Pharma, which has rights to Zevalin outside the United States, for access to pivotal trial data from the First-line Indolent Trial (FIT), which can potentially be used to expand the label in the U.S.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab infusions. Ytt
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
3. Sysmex America Awarded MedAssets Supply Chain Systems Hematology Contract Extension
4. AMDL Announces Filing of Extension on Third Quarter 2007 Form 10-QSB
5. Sinovac Requests Extension for Annual Shareholders Meeting
6. Healthcare Technologies Ltd. (NASDAQ: HCTL) Announces Extension of Letters of Intent to Acquire Majority Interest in Two Ethanol Plants
7. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
8. Resverlogix Share Option Extension
9. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
10. SENOMYX ANNOUNCES EXTENSION OF DISCOVERY AND DEVELOPMENT COLLABORATION WITH CADBURY PLC
11. Campbell Alliance Managed Markets Practice to Take Leadership Role at CBIs Formulary and Reimbursement Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... SunTrust Robinson Humphrey (STRH) today announced the ... research team in biotechnology and oilfield services.  ... demonstrates our commitment to providing our valued institutional ... decision making," said Biff Woodruff , Head ... significant investments in differentiated content at a time ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 A ... around the world is available from Strategic Consulting, ... companies. “ Industrial Microbiology Market Review, Fourth Edition: ... Market ” (IMMR—4) tracks and compares microbiology test ... North America, Europe and Asia, and forecasts future ...
(Date:8/27/2014)... August 27, 2014 Varian Medical Systems ... its current Salt Lake City manufacturing facility and allow ... Utah to ultimately create 1,000 new full time jobs ... , “Utah is home to hardworking people with immense ... credited with Varian’s success in the manufacturing of our ...
(Date:8/27/2014)... , Aug. 27, 2014   MSC , a ... safety, today announced the appointment of Mary Beth ... With 28 years of experience preparing companies for rapid ... as Executive Vice President of Corporate Development and Healthcare. ... improvement business , as well as corporate strategy and ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3MSC names Mary Beth Loesch President and CEO 2
... June 13, 2011 K-V Pharmaceutical Company (the "Company") (NYSE: ... for the fiscal year ended March 31, 2011 with the ... be holding an investor conference call today at 4:30 p.m. ... a general update on other company matters. Participants can listen ...
... 2011 Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTICD and MTA: ... list of preliminary additions to the Russell 3000® Index and ... 2011 at www.russell.com .  Russell Investments will finalize the ... on June 24, 2011. "We are very ...
... 10, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: ... of cord blood collection, laboratory testing, hematopoietic stem cell processing, ... results for the fourth quarter and fiscal year of 2011, ... Quarter of Fiscal 2011 Highlights Revenue in ...
Cached Biology Technology:K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 2K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 3K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 4K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 5K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 6K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 7Cell Therapeutics on Preliminary List of Additions to Russell 3000® Index and Russell Global Index 2Cell Therapeutics on Preliminary List of Additions to Russell 3000® Index and Russell Global Index 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 10
(Date:8/28/2014)... is pleased to announce the selection of Dr. Fred ... Membership acknowledges those who have served ESA for at ... of the Society that has reached an extraordinary level. ... Governing Board and then voted on by the ESA ... Ceremony at Entomology 2014, ESA,s Annual Meeting in Portland, ...
(Date:8/28/2014)... marine protected areas is needed to protect fish species ... from the Wildlife Conservation Society and other organizations, previous ... largest numbers of species, often at the expense of ... , Many vital ecological functions of ocean ... food for millions of people. This study uncovers ...
(Date:8/28/2014)... healthier for your neighbors than traditional cigarettes, but ... a new study from USC. , Scientists studying ... decrease in exposure to harmful particles, with close-to-zero ... to some harmful metals in second-hand e-cigarette smoke ... tobacco smoke contains high levels of polycyclic aromatic ...
Breaking Biology News(10 mins):Fred Baxendale selected as Honorary Member of the Entomological Society of America 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2Second-hand e-cig smoke compared to regular cigarette smoke 2
... to genetic disease, based on cells' own ability to correct ... the annual conference of the European Society of Human Genetics ... of replacing a faulty gene (commonly referred to as gene ... potential that already exists in human biology. , Professor Brunhilde ...
... provide biology researchers broader access to RNA interference, a ... interference has recently emerged as an important tool in ... in disease. , Writing in the Journal of Immunological ... from The Children's Hospital of Philadelphia combined laboratory technologies ...
... Researchers at Rensselaer Polytechnic Institute, the Marine Biological Laboratory ... Health Sciences Center have discovered the presence of the ... inside each cell that assures proper cell division. ... early edition of the journal Proceedings of the National ...
Cached Biology News:'Smart' genetic therapy helps the body to heal itself 2'Smart' genetic therapy helps the body to heal itself 3'Smart' genetic therapy helps the body to heal itself 4Interfering RNA silences genes in 'slippery' immune cells 2Interfering RNA silences genes in 'slippery' immune cells 3RNA found in the cellular centrosome of surf clams 2
This modular benchtop laminar flow hood forces air through a 99.99% efficient HEPA filter to create a clean processing area. Options include a work bench, ionizaing bar, and air velocity gauge....
...
... Thermo Scientific ChromQuest Chromatography Data System ... digital data acquisition, chromatography data processing ... Accela High Speed LC. The companys ... to maximize the benefits of Thermo ...
...
Biology Products: